Understanding China: News Investments Community

PR Archives:  LatestBy Company By Date


Press Release -- August 1st, 2012

SciClone Pharmaceuticals to Report Financial Results for the Second Quarter 2012 on August 8th

FOSTER CITY, CA– (Marketwire) –08/01/12–SciClone Pharmaceuticals, Inc.(NASDAQ: SCLN) today announced that it plans to report second quarter 2012 financial results onWednesday, August 8, 2012. SciClone will host a conference call and webcast to provide a business and product update at4:30 pm ETthat day. The call will be hosted byFriedhelm Blobel, Ph.D., President and CEO, andGary Titus, Senior Vice President and CFO.

LIVE CALL: 866-788-0538 (U.S./Canada) 857-350-1676 (International) Passcode: 78741367

REPLAY: 888-286-8010 (U.S./Canada) 617-801-6888 (International) Passcode: 66427555 (Replay available fromWednesday, August 8, 2012, at6:30 pm ET until 11:59 pm ETonWednesday, August 15, 2012)

The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone’s website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.

About SciClone

SciClone Pharmaceuticalsis a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in Chinaand a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 15 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates.

Aggrastat is a registered trademark ofMedicure International Inc.inthe United States, andIroko Cardio LLCin numerous other countries.

SciClone,SciClone Pharmaceuticals, theSciClone Pharmaceuticalsdesign, the SciClone logo and ZADAXIN are registered trademarks ofSciClone Pharmaceuticals, Inc.inthe United Statesand numerous other countries.

Corporate Contacts:

Gary Titus

Chief Financial Officer

650.358.3456

gtitus@sciclone.com

Jane Green

Investors/Media

650.358.1447

jgreen@sciclone.com

Source:SciClone Pharmaceuticals, Inc.

News Provided by Acquire Media

PR Archives: Latest, By Company, By Date